Literature DB >> 23824846

Pharmacogenomics: historical perspective and current status.

Rosane Charlab1, Lei Zhang.   

Abstract

Pharmacogenomics and its predecessor pharmacogenetics study the contribution of genetic factors to the interindividual variability in drug efficacy and safety. One of the major goals of pharmacogenomics is to tailor drugs to individuals based on their genetic makeup and molecular profile. From early findings in the 1950s uncovering inherited deficiencies in drug metabolism that explained drug-related adverse events, to nowadays genome-wide approaches assessing genetic variation in multiple genes, pharmacogenomics has come a long way. The evolution of pharmacogenomics has paralleled the evolution of genotyping technologies, the completion of the human genome sequencing and the HapMap project. Despite these advances, the implementation of pharmacogenomics in clinical practice has yet been limited. Here we present an overview of the history and current applications of pharmacogenomics in patient selection, dosing, and drug development with illustrative examples of these categories. Some of the challenges in the field and future perspectives are also presented.

Entities:  

Mesh:

Year:  2013        PMID: 23824846     DOI: 10.1007/978-1-62703-435-7_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

Review 1.  Precision medicine journey through omics approach.

Authors:  Mandana Hasanzad; Negar Sarhangi; Sima Ehsani Chimeh; Nayereh Ayati; Monireh Afzali; Fatemeh Khatami; Shekoufeh Nikfar; Hamid Reza Aghaei Meybodi
Journal:  J Diabetes Metab Disord       Date:  2021-11-24

Review 2.  A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges.

Authors:  Asif Sukri; Mohd Zaki Salleh; Collen Masimirembwa; Lay Kek Teh
Journal:  Pharmacogenomics J       Date:  2022-03-22       Impact factor: 3.245

Review 3.  Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.

Authors:  Kishan S Parikh; Jonathan P Piccini
Journal:  Curr Heart Fail Rep       Date:  2017-12

4.  Augmented case-only designs for randomized clinical trials with failure time endpoints.

Authors:  James Y Dai; Xinyi Cindy Zhang; Ching-Yun Wang; Charles Kooperberg
Journal:  Biometrics       Date:  2015-09-08       Impact factor: 2.571

5.  Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.

Authors:  Nayyereh Ayati; Monireh Afzali; Mandana Hasanzad; Abbas Kebriaeezadeh; Ali Rajabzadeh; Shekoufeh Nikfar
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.